Cargando…

PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study

Although immune checkpoints inhibitors have exhibited promising activity in clinical trials in non-small cell lung cancer (NSCLC) patients, the current programmed cell death-ligand 1 (PD-L1) assays are inconsistent in terms of the staining analysis and scoring system used. To verify the interchangea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyojin, Kwon, Hyun Jung, Park, Soo Young, Park, Eunhyang, Chung, Jin-Haeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716747/ https://www.ncbi.nlm.nih.gov/pubmed/29228707 http://dx.doi.org/10.18632/oncotarget.21567

Ejemplares similares

Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer
por: Kim, Hyojin, et al.
Publicado: (2018)

PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
por: Kim, Hyojin, et al.
Publicado: (2019)

Correction of acknowledgments: PD-L1 testing in non-small cell lung cancer: past, present, and future
por: Kim, Hyojin, et al.
Publicado: (2020)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
por: Ahn, Hyein, et al.
Publicado: (2018)

Heterotopic Pancreas in Omphalomesenteric Duct Remnant Results in Persistent Umbilical Discharge
por: Park, Eunhyang, et al.
Publicado: (2014)

Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Kim, Hyojin, et al.
Publicado: (2022)

Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
por: Walsh, Robert J., et al.
Publicado: (2020)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
por: Yokoyama, Shintaro, et al.
Publicado: (2020)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer
por: Schmidt, Emmett V.
Publicado: (2018)

Aquaporin 1 Is an Independent Marker of Poor Prognosis in Lung Adenocarcinoma
por: Yun, Sumi, et al.
Publicado: (2016)

PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy
por: Delmas, Dominique, et al.
Publicado: (2021)

Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
por: Park, Seongho, et al.
Publicado: (2019)

Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies
por: Belliere, Julie, et al.
Publicado: (2021)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma
por: Park, Eunhyang, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
por: Fujisawa, Takuo, et al.
Publicado: (2019)

Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2018)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis
por: Schneider, Stephanie, et al.
Publicado: (2017)

Mesonephric-like Adenocarcinoma of the Uterine Corpus: Genomic and Immunohistochemical Profiling with Comprehensive Clinicopathological Analysis of 17 Consecutive Cases from a Single Institution
por: Koh, Hyun-Hee, et al.
Publicado: (2023)

Immunohistochemical demonstration of alteration of β-catenin during tumor metastasis by different mechanisms according to histology in lung cancer
por: XU, XIANHUA, et al.
Publicado: (2015)

Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
por: Liu, Chang, et al.
Publicado: (2021)

Prognostic significance of stem cell-related marker expression and its correlation with histologic subtypes in lung adenocarcinoma
por: Park, Eunhyang, et al.
Publicado: (2016)

Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2020)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2020)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis
por: Shi, Haotong, et al.
Publicado: (2023)

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
por: Ragusa, Francesca, et al.
Publicado: (2022)

A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma
por: Sakane, Tadashi, et al.
Publicado: (2018)

Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung
por: Han, Yeon Bi, et al.
Publicado: (2019)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
por: Yin, Jianqiong, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer
por: O’Meara, Connor H., et al.
Publicado: (2023)

Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
por: Oualla, Karima, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_glvh24iuikol8r670aiomucviv